Skip to main content

Swiss pharma boom rolls on; Riksbank biding its time

The resilience of the pharmaceutical sector masked much deeper problems in the Swiss manufacturing sector in Q2, but signs that German industry continued to rebound in August bode well given strong supply-chain links. Next week, the first estimates of Q2 GDP from Norway and Switzerland are likely to add to the evidence that Switzerland and the Nordic economies got off pretty lightly by European standards.

Become a client to read more

This is premium content that requires an active Capital Economics subscription to view.

Already have an account?

You may already have access to this premium content as part of a paid subscription.

Sign in to read the content in full or get details of how you can access it

Register for free

Sign up for a free account to gain:

  • Unlock additional content
  • Register for Capital Economics events
  • Receive email updates and economist-curated newsletters
  • Request a free trial of our services


Get access